Nuformix Plc (NFX) Price & Analysis

Q: What was Nuformix Plc’s price range in the past 12 months?

Nuformix Plc lowest share price was 0.07 p and its highest was 0.56 p in the past 12 months.

Q: What is Nuformix Plc’s market cap?

Nuformix Plc’s market cap is £4.32M.

Q: When is Nuformix Plc’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

Q: Is Nuformix Plc overvalued?

According to Wall Street analysts Nuformix Plc’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Q: Does Nuformix Plc pay dividends?

Nuformix Plc does not currently pay dividends.

Q: What is Nuformix Plc’s EPS estimate?

Nuformix Plc’s EPS estimate for its next earnings report is not yet available.

Q: How many shares outstanding does Nuformix Plc have?

Nuformix Plc has 2,109,750,000 shares outstanding.

Q: Which hedge fund is a major shareholder of Nuformix Plc?

Currently, no hedge funds are holding shares in GB:NFX

Q: What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Compare

10 Followers

NFX Stock Chart & Stats

0.23 p

<0.01 p(2.11%)

At close: Jan 09 4:00 PM EST

0.23 p

<0.01 p(2.11%)

Day’s Range― - ―

52-Week Range0.07 p - 0.56 p

Previous CloseN/A

Volume1.00M

Average Volume (3M)97.88M

Market Cap

£4.32M

Enterprise Value4.23M

Total Cash (Recent Filing)£97.55K

Total Debt (Recent Filing)£0.00

Price to Earnings (P/E)―

Beta-0.38

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding2,109,750,000

10 Day Avg. Volume69,476,590

30 Day Avg. Volume97,880,797

Financial Highlights & Ratios

PEG Ratio0.06

Price to Book (P/B)5.17

Price to Sales (P/S)0.00

P/FCF Ratio-6.35

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Low LeverageZero reported debt materially reduces financial risk and preserves strategic flexibility. For a pre-revenue biotech, low leverage lengthens the time available to advance clinical or partnering milestones without immediate debt servicing pressures, improving resilience over the next several months.

Repurposing/formulation ModelA strategy centered on reformulating approved drugs can shorten development timelines, lower clinical risk and cost versus de novo discovery. This business model is structurally attractive to partners and licensors and supports a sustainable path to value creation through collaborations or out-licensing.

Evidence Of Cost TighteningThe marked reduction in the 2025 loss versus 2024 implies management actions to curb cash burn. Sustained cost discipline can materially extend runway for clinical development or partnering discussions, improving execution optionality over the coming quarters.

Bears Say

No RevenueThe absence of reported revenue across multiple years signals a stalled commercialization profile and high reliance on pipeline value or external funding. Without near-term product sales, the business must secure financing or deals to sustain operations and progress candidates.

Weak Cash GenerationPersistent negative operating and free cash flows create ongoing funding needs. Continued cash burn increases dilution risk or forces asset sales/partner concessions, constraining the company's ability to independently advance programs or weather trial delays in the medium term.

Shrinking Equity/assetsA materially reduced equity and asset base leaves limited financial buffer for setbacks. Small balance-sheet size weakens negotiating leverage with partners and heightens solvency risk if additional funding is delayed or more capital is required to progress development milestones.

Nuformix Plc News

Nuformix Raises £1m to Accelerate NXP002 Fibrosis Programme

Nuformix Plc ( ($GB:NFX) ) has shared an announcement. Nuformix plc has raised £1.0 million via a placing...

4d ago

Nuformix Wins US Orphan Drug Status for IPF Candidate NXP002

The latest update is out from Nuformix Plc ( ($GB:NFX) ). Nuformix has secured U.S. Food and Drug...

5d ago

Nuformix Wins Strong Shareholder Backing as All AGM Resolutions Pass

Nuformix Plc ( ($GB:NFX) ) has issued an update. Nuformix plc reported that all resolutions at its Annual...

12d ago

Nuformix Posts 2025 Annual Report and Sets Date for 2026 AGM

The latest update is out from Nuformix Plc ( ($GB:NFX) ). Nuformix plc has published its Annual Financial...

1M ago

Nuformix Sharpens Focus on Partnering Lead IPF Drug NXP002 as Preclinical Data Strengthen Case

Nuformix Plc ( ($GB:NFX) ) just unveiled an update. In its annual results for the year to 30...

2M ago

Nuformix PLC Updates Total Voting Rights Following New Share Issuance

Nuformix Plc ( ($GB:NFX) ) has shared an announcement. Nuformix PLC has announced the issuance of new ordinary...

4M ago

Nuformix Awaits FDA Response on Orphan Drug Designation for IPF Treatment

The latest announcement is out from Nuformix Plc ( ($GB:NFX) ). Nuformix plc has announced that the US...

4M ago

Nuformix plc Successfully Completes Oversubscribed Open Offer

Nuformix Plc ( ($GB:NFX) ) has shared an update. Nuformix plc announced the results of its underwritten Open...

4M ago

Nuformix Launches £228,081 Open Offer to Advance Drug Repurposing Initiatives

Nuformix Plc ( ($GB:NFX) ) has issued an update. Nuformix plc has announced an underwritten Open Offer to...

5M ago

Nuformix Appoints New Auditor Amid Strategic Developments

An announcement from Nuformix Plc ( ($GB:NFX) ) is now available. Nuformix plc has appointed Kreston Reeves Audit...

5M ago

NFX FAQ

What was Nuformix Plc’s price range in the past 12 months?

Nuformix Plc lowest share price was 0.07 p and its highest was 0.56 p in the past 12 months.

What is Nuformix Plc’s market cap?

Nuformix Plc’s market cap is £4.32M.

When is Nuformix Plc’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Nuformix Plc’s earnings last quarter?

Currently, no data Available

Is Nuformix Plc overvalued?

According to Wall Street analysts Nuformix Plc’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Nuformix Plc pay dividends?

Nuformix Plc does not currently pay dividends.

What is Nuformix Plc’s EPS estimate?

Nuformix Plc’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Nuformix Plc have?

Nuformix Plc has 2,109,750,000 shares outstanding.

What happened to Nuformix Plc’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Nuformix Plc?

Currently, no hedge funds are holding shares in GB:NFX

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Nuformix Plc

Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications. Nuformix plc was founded in 2008 and is based in London, the United Kingdom.